SPRY
ARS Pharmaceuticals Inc

2,186
Loading...
Loading...
News
all
press releases
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -12.20% and +3.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of +26.09% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks·1mo ago
News Placeholder
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?
Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago
News Placeholder
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?
The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'
ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks·2mo ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
Zacks·4mo ago

Latest SPRY News

View

Advertisement. Remove ads.

Advertisement. Remove ads.